Treatment of Sickle Cell Anemia with Hydroxyurea and Erythropoietin
- 9 August 1990
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 323 (6) , 366-372
- https://doi.org/10.1056/nejm199008093230602
Abstract
Hydroxyurea increases the production of fetal hemoglobin (hemoglobin F) in patients with sickle cell anemia and therefore has the potential for alleviating both the hemolytic and vaso-occlusive manifestations of the disease. There is preliminary evidence that recombinant human erythropoietin may also increase hemoglobin F production.This publication has 60 references indexed in Scilit:
- Hematologic Responses of Patients with Sickle Cell Disease to Treatment with HydroxyureaNew England Journal of Medicine, 1990
- Treatment of the Anemia of Progressive Renal Failure with Recombinant Human ErythropoietinNew England Journal of Medicine, 1989
- Stimulation of Fetal Hemoglobin Synthesis by Erythropoietin in BaboonsNew England Journal of Medicine, 1987
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987
- Stimulation of F-Cell Production in Patients with Sickle-Cell Anemia Treated with Cytarabine or HydroxyureaNew England Journal of Medicine, 1985
- Augmentation of Fetal-Hemoglobin Production in Anemic Monkeys by HydroxyureaNew England Journal of Medicine, 1984
- Molecular topology in crystals and fibers of hemoglobin SJournal of Molecular Biology, 1981
- A Study of Induced Hyponatremia in the Prevention and Treatment of Sickle-Cell CrisisNew England Journal of Medicine, 1980
- Erythrocyte Adherence to Endothelium in Sickle-Cell AnemiaNew England Journal of Medicine, 1980
- Individual Variation in the Production and Survival of F Cells in Sickle-Cell DiseaseNew England Journal of Medicine, 1978